These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 15687128

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.
    Mobarrez F, He S, Bröijersen A, Wiklund B, Antovic A, Antovic J, Egberg N, Jörneskog G, Wallén H.
    Thromb Haemost; 2011 Aug; 106(2):344-52. PubMed ID: 21614411
    [Abstract] [Full Text] [Related]

  • 24. Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction.
    Santos MT, Fuset MP, Ruano M, Moscardó A, Valles J.
    Am J Cardiol; 2009 Dec 15; 104(12):1618-23. PubMed ID: 19962464
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina.
    Tousoulis D, Bosinakou E, Kotsopoulou M, Antoniades C, Katsi V, Stefanadis C.
    Int J Cardiol; 2006 Jan 26; 106(3):333-7. PubMed ID: 16337041
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome.
    Mälarstig A, Lindahl B, Wallentin L, Siegbahn A.
    Arterioscler Thromb Vasc Biol; 2006 Jul 26; 26(7):1667-73. PubMed ID: 16627810
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy.
    Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, Falco A, Cuccurullo F, Davì G.
    Circulation; 2002 Jul 23; 106(4):399-402. PubMed ID: 12135935
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. CD40 ligand: a novel target in the fight against cardiovascular disease.
    Vishnevetsky D, Kiyanista VA, Gandhi PJ.
    Ann Pharmacother; 2004 Sep 23; 38(9):1500-8. PubMed ID: 15280513
    [Abstract] [Full Text] [Related]

  • 38. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA.
    Int J Cardiol; 2005 Oct 10; 104(3):338-45. PubMed ID: 16186066
    [Abstract] [Full Text] [Related]

  • 39. Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia.
    Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT.
    Acta Cardiol; 2006 Jun 10; 61(3):263-9. PubMed ID: 16869445
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.